BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting

  Inovelon will be presented at the 71st AES Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.

  November 27, 2017

   · 

  2 min read
• 

  Business

  Little-Known Synthorx Names Former Cleave CEO as New Leader

  Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Teva Shakes Up C-Suite in Restructuring

  Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• Immunochina Lands $7.5M for CAR-T Drug Trials

  Immunochina raised $7.5M to support clinical trials of its CAR-T product for lymphoma.

  November 27, 2017

   · 

  1 min read
• 3D Medicines Raises $101M for Cancer Diagnostics and Drugs

  The funding was led by China Reform Holdings and joined by ChinaEquity Group and several unnamed investors.

  November 27, 2017

   · 

  1 min read
• 

  Policy

  Stem Cells Ready for Prime Time?

  A look at the FDA’s long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Business

  Our Insider HHS Secretary

  A look at President Trump’s new pick for HHS Secretary.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Biotech Bay

  Are We Reaching the Biotech Singularity?

  The “singularity” is a term favored by futurists like Google exec Ray Kurzweill, typically in reference to computer technology.

  November 27, 2017

   · 

  4 min read

   · 

  Karl Thiel
• 

  Business

  Does Genentech Have a New Mega-Blockbuster?

  Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Drug Development

  ASH Heats Up, Plus Alkermes’ Huge I-Told-Ya-So

  The drug developed by Alkermes took a lot of flack but proved effective in a recent study.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel